VIGIV
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Complication of Smallpox Vaccination
Conditions
Complication of Smallpox Vaccination
Trial Timeline
Aug 1, 2007 → Aug 1, 2027
NCT ID
NCT01374984About VIGIV
VIGIV is a pre-clinical stage product being developed by Emergent BioSolutions for Complication of Smallpox Vaccination. The current trial status is recruiting. This product is registered under clinical trial identifier NCT01374984. Target conditions include Complication of Smallpox Vaccination.
What happened to similar drugs?
13 of 17 similar drugs in Complication of Smallpox Vaccination were approved
Approved (13) Terminated (2) Active (3)
Hype Score Breakdown
Clinical
3
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01374984 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Complication of Smallpox Vaccination